Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma

Ludimila Cavalcante, Akansha Chowdhary, Jeffrey Alan Sosman, Sunandana Chandra*

*Corresponding author for this work

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The field of tumor immunology has faced many complex challenges over the last century, but the approval of immune checkpoint inhibitors (anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] and anti-programmed cell death-1 [PD-1]/PD-ligand 1 [PD-L1]) and talimogene laherparepvec (T-VEC) for the treatment of metastatic melanoma have awakened a new wave of interest in cancer immunotherapy. Additionally, combinations of vaccines and oncolytic viral therapies with immune checkpoint inhibitors and other systemic agents seem to be promising synergistic strategies to further boost the immune response against cancer. These combinations are undergoing clinical investigation, and if successful, will hopefully soon become available to patients. Here, we review key basic concepts of tumor-induced immune suppression in malignant melanoma, the historical perspective around vaccine development in melanoma, and advances in oncolytic viral therapies. We also discuss the emerging role for combination approaches with different immunomodulatory agents as well as new developments in personalized immunization approaches.

Original languageEnglish (US)
Pages (from-to)657-670
Number of pages14
JournalAmerican Journal of Clinical Dermatology
Volume19
Issue number5
DOIs
StatePublished - Oct 1 2018

Fingerprint

Melanoma
Vaccination
Clinical Trials
CD274 Antigen
Neoplasms
Combined Vaccines
Cytotoxic T-Lymphocytes
Allergy and Immunology
Immunotherapy
Immunization
Therapeutics
Vaccines
Proteins

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{decd4c9b4d334715bb74fee4944cd848,
title = "Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma",
abstract = "The field of tumor immunology has faced many complex challenges over the last century, but the approval of immune checkpoint inhibitors (anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] and anti-programmed cell death-1 [PD-1]/PD-ligand 1 [PD-L1]) and talimogene laherparepvec (T-VEC) for the treatment of metastatic melanoma have awakened a new wave of interest in cancer immunotherapy. Additionally, combinations of vaccines and oncolytic viral therapies with immune checkpoint inhibitors and other systemic agents seem to be promising synergistic strategies to further boost the immune response against cancer. These combinations are undergoing clinical investigation, and if successful, will hopefully soon become available to patients. Here, we review key basic concepts of tumor-induced immune suppression in malignant melanoma, the historical perspective around vaccine development in melanoma, and advances in oncolytic viral therapies. We also discuss the emerging role for combination approaches with different immunomodulatory agents as well as new developments in personalized immunization approaches.",
author = "Ludimila Cavalcante and Akansha Chowdhary and Sosman, {Jeffrey Alan} and Sunandana Chandra",
year = "2018",
month = "10",
day = "1",
doi = "10.1007/s40257-018-0359-4",
language = "English (US)",
volume = "19",
pages = "657--670",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors

T2 - Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma

AU - Cavalcante, Ludimila

AU - Chowdhary, Akansha

AU - Sosman, Jeffrey Alan

AU - Chandra, Sunandana

PY - 2018/10/1

Y1 - 2018/10/1

N2 - The field of tumor immunology has faced many complex challenges over the last century, but the approval of immune checkpoint inhibitors (anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] and anti-programmed cell death-1 [PD-1]/PD-ligand 1 [PD-L1]) and talimogene laherparepvec (T-VEC) for the treatment of metastatic melanoma have awakened a new wave of interest in cancer immunotherapy. Additionally, combinations of vaccines and oncolytic viral therapies with immune checkpoint inhibitors and other systemic agents seem to be promising synergistic strategies to further boost the immune response against cancer. These combinations are undergoing clinical investigation, and if successful, will hopefully soon become available to patients. Here, we review key basic concepts of tumor-induced immune suppression in malignant melanoma, the historical perspective around vaccine development in melanoma, and advances in oncolytic viral therapies. We also discuss the emerging role for combination approaches with different immunomodulatory agents as well as new developments in personalized immunization approaches.

AB - The field of tumor immunology has faced many complex challenges over the last century, but the approval of immune checkpoint inhibitors (anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] and anti-programmed cell death-1 [PD-1]/PD-ligand 1 [PD-L1]) and talimogene laherparepvec (T-VEC) for the treatment of metastatic melanoma have awakened a new wave of interest in cancer immunotherapy. Additionally, combinations of vaccines and oncolytic viral therapies with immune checkpoint inhibitors and other systemic agents seem to be promising synergistic strategies to further boost the immune response against cancer. These combinations are undergoing clinical investigation, and if successful, will hopefully soon become available to patients. Here, we review key basic concepts of tumor-induced immune suppression in malignant melanoma, the historical perspective around vaccine development in melanoma, and advances in oncolytic viral therapies. We also discuss the emerging role for combination approaches with different immunomodulatory agents as well as new developments in personalized immunization approaches.

UR - http://www.scopus.com/inward/record.url?scp=85052911786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052911786&partnerID=8YFLogxK

U2 - 10.1007/s40257-018-0359-4

DO - 10.1007/s40257-018-0359-4

M3 - Review article

C2 - 29961183

AN - SCOPUS:85052911786

VL - 19

SP - 657

EP - 670

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - 5

ER -